echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Approximately 70% of skin tumors have shrunk significantly

    Approximately 70% of skin tumors have shrunk significantly

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 12, 2021, Medivir announced that its topical histone deacetylase (HDAC) inhibitor remetinostat has obtained positive results in a phase 2 clinical trial for adjuvant treatment of patients with basal cell carcinoma (BCC)


    BCC is a common skin cancer, and the current main treatment is surgical resection


    Among the 33 tumors analyzed in the final analysis, the overall response rate (ORR) was 69.


    ▲Remetinostat molecular structure (picture source: PubChem)

    Previously, a dose-escalation phase 2 trial of the drug in patients with mycosis fungal skin T-cell lymphoma (MF-CTCL) showed that the severity of skin lesions in patients decreased, with an objective response rate (ORR) of up to 40% At the highest dose, the severity of itching in 80% of patients was clinically significantly reduced


    (The original text has been deleted)

    Reference materials:

    [1] Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research.


    [2] Kilgour, JM, et, al.


    [3] A New Type of Gel Shows Promise Against Common Type of Skin Cancer.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.